Guardant Health Inc (GH)

$99.94 +3.23 (3.34%)
Market Cap 12.82B
Revenue (ttm) 982.02M
Net Income (ttm) -416.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -42.39%
Debt to Equity Ratio -8.30
Volume 2,546,900
Avg Vol 2,008,474
Day's Range N/A - N/A
Shares Out 132.60M
Stochastic %K 96%
Beta 1.48
Analysts Strong Sell
Price Target $131.20

Company Profile

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling t...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 855 698 8887
Fax: 888 974 4258
Address:
3100 Hanover Street, Palo Alto, United States
Gator5326
Gator5326 May. 13 at 1:54 PM
$GH As of May 2026, Guardant Health (GH) stock is experiencing strong bullish sentiment with multiple price target increases following Q1 2026 results that showed 48% year-over-year revenue growth. Analysts have raised targets to a range of $130–$180, indicating a potential 29%-47% upside driven by strong oncology test volumes and Shield screening momentum.
0 · Reply
BeeDecay
BeeDecay May. 13 at 11:44 AM
$PSNL $NTRA $GH , With IO reimbursement in place now it might be the case that little Personalis will eat some of the others' lunch quite soon.
0 · Reply
Gator5326
Gator5326 May. 12 at 10:21 PM
$GH https://bofa.veracast.com/webcasts/bofa/healthcare2026/15d168.cfm 🚀🚀🚀
0 · Reply
Gator5326
Gator5326 May. 12 at 10:20 PM
$GH ACS ACS ACS 😎😎😎
0 · Reply
Shlobby
Shlobby May. 12 at 2:40 PM
$GH took some oct calls
0 · Reply
CapitalMonk
CapitalMonk May. 12 at 1:03 AM
$GH Price: $96.71 (+1.06%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.48% RSI: 62.1 | Momentum: Strong Momentum Volume: +1.5% vs avg Volatility: 2.84% Support: $79.01 | Resistance: $98.50 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
WOLFSTREET
WOLFSTREET May. 11 at 6:02 PM
$GH Press Like!
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 12:47 PM
$GH Current Stock Price: $95.78 Contracts to trade: $95.0 GH May 15 2026 Call Entry: $3.15 Exit: $4.46 ROI: 42% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
vjtweet
vjtweet May. 8 at 4:54 PM
$GH not blowout results.. but should continue the upward path. Holding a position. To add above 100.
1 · Reply
JFDI
JFDI May. 8 at 1:50 PM
$GH 30/40wk SMA to stage 2 continuation.
1 · Reply
Latest News on GH
Guardant Health Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 1:40 PM EDT - 22 hours ago

Guardant Health Transcript: Bank of America Global Healthcare Conference 2026

Guardant Health price target raised to $135 from $130 at Piper Sandler

2026-05-12T11:17:01.000Z - 1 day ago

Guardant Health price target raised to $135 from $130 at Piper Sandler

Guardant Health price target raised to $95 from $90 at Evercore ISI

2026-05-08T18:23:29.000Z - 4 days ago

Guardant Health price target raised to $95 from $90 at Evercore ISI

Guardant Health price target raised to $129 from $120 at Baird

2026-05-08T16:40:48.000Z - 4 days ago

Guardant Health price target raised to $129 from $120 at Baird

Guardant Health price target raised to $135 from $130 at JPMorgan

2026-05-08T12:40:59.000Z - 5 days ago

Guardant Health price target raised to $135 from $130 at JPMorgan

Guardant Health price target raised to $120 from $115 at Barclays

2026-05-08T10:30:55.000Z - 5 days ago

Guardant Health price target raised to $120 from $115 at Barclays

Guardant Health reports Q1 adjusted EPS (45c), consensus (47c)

2026-05-07T21:10:19.000Z - 5 days ago

Guardant Health reports Q1 adjusted EPS (45c), consensus (47c)

Guardant Health raises FY26 revenue view to $1.3B-$1.32B from $1.25B-$1.28B

2026-05-07T21:07:53.000Z - 5 days ago

Guardant Health raises FY26 revenue view to $1.3B-$1.32B from $1.25B-$1.28B

Guardant Health Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 5 days ago

Guardant Health Earnings Call Transcript: Q1 2026

Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

May 7, 2026, 4:05 PM EDT - 5 days ago

Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Guardant Health receives FDA approval for Guardant360 CDx

2026-05-04T12:34:42.000Z - 9 days ago

Guardant Health receives FDA approval for Guardant360 CDx

ARVN PFE

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

May 4, 2026, 8:05 AM EDT - 9 days ago

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

Guardant falls after FDA panel votes down AstraZeneca breast cancer drug

2026-04-30T18:15:59.000Z - 12 days ago

Guardant falls after FDA panel votes down AstraZeneca breast cancer drug

AZN

Guardant Health announces multi-year strategic collaboration with Nuvalent

2026-04-30T16:05:45.000Z - 12 days ago

Guardant Health announces multi-year strategic collaboration with Nuvalent

NUVL

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

Apr 30, 2026, 8:05 AM EDT - 13 days ago

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

NUVL

Guardant Health to Participate in Upcoming Investor Conferences

Apr 29, 2026, 4:05 PM EDT - 13 days ago

Guardant Health to Participate in Upcoming Investor Conferences

Overhang should lift for Guardant after AstraZeneca AdCom, says Leerink

2026-04-28T18:45:21.000Z - 14 days ago

Overhang should lift for Guardant after AstraZeneca AdCom, says Leerink

AZN

Guardant falls after FDA briefing documents for camizestrant

2026-04-28T18:10:20.000Z - 14 days ago

Guardant falls after FDA briefing documents for camizestrant

AZN

Guardant Health Chief Medical Officer resigns effective May 8

2026-04-27T21:15:16.000Z - 15 days ago

Guardant Health Chief Medical Officer resigns effective May 8

Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026

Apr 16, 2026, 4:05 PM EDT - 26 days ago

Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026

Guardant Health price target lowered to $115 from $130 at Barclays

2026-04-14T10:48:23.000Z - 4 weeks ago

Guardant Health price target lowered to $115 from $130 at Barclays

Citi adds ‘upside 90-day catalyst watch’ on Guardant Health

2026-04-07T10:10:33.000Z - 5 weeks ago

Citi adds ‘upside 90-day catalyst watch’ on Guardant Health

Guardant Health price target lowered to $90 from $110 at Evercore ISI

2026-04-06T12:18:53.000Z - 5 weeks ago

Guardant Health price target lowered to $90 from $110 at Evercore ISI

Guardant Health added to Q2 Tactical Ideas List at Wells Fargo

2026-04-01T10:45:12.000Z - 6 weeks ago

Guardant Health added to Q2 Tactical Ideas List at Wells Fargo

Guardant Health announces evidence generated from InfinityAI

2026-03-30T12:37:10.000Z - 6 weeks ago

Guardant Health announces evidence generated from InfinityAI

Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

Mar 30, 2026, 8:05 AM EDT - 6 weeks ago

Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

Guardant Health, Verana Health announce new partnership

2026-03-24T13:20:46.000Z - 7 weeks ago

Guardant Health, Verana Health announce new partnership

Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data

Mar 24, 2026, 9:15 AM EDT - 7 weeks ago

Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data

Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026

Mar 18, 2026, 8:05 AM EDT - 2 months ago

Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

Mar 16, 2026, 8:05 AM EDT - 2 months ago

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare

Mar 13, 2026, 8:05 AM EDT - 2 months ago

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare

Guardant Health Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 1:00 PM EDT - 2 months ago

Guardant Health Transcript: Barclays 28th Annual Global Healthcare Conference

Guardant Health Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 1:00 PM EDT - 2 months ago

Guardant Health Transcript: Leerink Global Healthcare Conference 2026

Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

Mar 10, 2026, 8:05 AM EDT - 2 months ago

Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

Guardant Health Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:50 AM EST - 2 months ago

Guardant Health Transcript: TD Cowen 46th Annual Health Care Conference

Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America

Mar 4, 2026, 7:00 AM EST - 2 months ago

Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America

Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened

Mar 3, 2026, 7:00 AM EST - 2 months ago

Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 27, 2026, 4:05 PM EST - 2 months ago

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guardant Health Earnings Call Transcript: Q4 2025

Feb 19, 2026, 4:30 PM EST - 2 months ago

Guardant Health Earnings Call Transcript: Q4 2025

Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

Feb 19, 2026, 4:05 PM EST - 2 months ago

Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open

Feb 12, 2026, 2:35 PM EST - 3 months ago

Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

Feb 2, 2026, 8:05 AM EST - 3 months ago

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Jan 29, 2026, 4:05 PM EST - 3 months ago

Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Jan 22, 2026, 8:05 AM EST - 3 months ago

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

Jan 19, 2026, 8:05 AM EST - 4 months ago

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

Guardant Health Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 PM EST - 4 months ago

Guardant Health Transcript: 44th Annual J.P. Morgan Healthcare Conference

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results

Jan 11, 2026, 5:00 PM EST - 4 months ago

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results

Guardant Health's Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families

Jan 8, 2026, 8:05 AM EST - 4 months ago

Guardant Health's Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families

Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 29, 2025, 4:05 PM EST - 4 months ago

Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Global Healthy Living Foundation and Guardant Health Announce Partnership to Advance Awareness of Early Colorectal Cancer Detection and Improve Access to Screening

Dec 29, 2025, 10:10 AM EST - 4 months ago

Global Healthy Living Foundation and Guardant Health Announce Partnership to Advance Awareness of Early Colorectal Cancer Detection and Improve Access to Screening

Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

Dec 11, 2025, 8:05 AM EST - 5 months ago

Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy

Dec 9, 2025, 8:05 AM EST - 5 months ago

Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

Dec 5, 2025, 8:05 AM EST - 5 months ago

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

Guardant Health Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 8:30 AM EST - 5 months ago

Guardant Health Transcript: Piper Sandler 37th Annual Healthcare Conference

These 15 stocks are still showing momentum — and a market-beating edge

Nov 20, 2025, 3:45 PM EST - 6 months ago

These 15 stocks are still showing momentum — and a market-beating edge

BE CIEN CRDO INSM LITE MP MU

Guardant Health Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 4:30 AM EST - 6 months ago

Guardant Health Transcript: Jefferies London Healthcare Conference 2025

Guardant Health Transcript: 7th Annual Healthcare Symposium

Nov 14, 2025, 8:50 AM EST - 6 months ago

Guardant Health Transcript: 7th Annual Healthcare Symposium

Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access

Nov 12, 2025, 8:05 AM EST - 6 months ago

Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access

Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring

Nov 10, 2025, 8:05 AM EST - 6 months ago

Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring

New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response

Nov 6, 2025, 8:05 AM EST - 6 months ago

New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response

Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients

Nov 5, 2025, 4:05 PM EST - 6 months ago

Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients

Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering

Nov 5, 2025, 2:15 AM EST - 6 months ago

Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering

Guardant Health Announces Pricing of Upsized Public Offering of Common Stock

Nov 5, 2025, 2:15 AM EST - 6 months ago

Guardant Health Announces Pricing of Upsized Public Offering of Common Stock

Guardant Health Announces Proposed Public Offering of Common Stock

Nov 4, 2025, 4:39 PM EST - 6 months ago

Guardant Health Announces Proposed Public Offering of Common Stock

Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033

Nov 4, 2025, 4:38 PM EST - 6 months ago

Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033

Guardant Health Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 6 months ago

Guardant Health Earnings Call Transcript: Q3 2025

Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Oct 29, 2025, 4:05 PM EDT - 6 months ago

Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights

Oct 27, 2025, 8:05 AM EDT - 7 months ago

Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

Oct 26, 2025, 3:01 PM EDT - 7 months ago

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025

Oct 15, 2025, 4:57 PM EDT - 7 months ago

Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025

Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025

Oct 9, 2025, 4:05 PM EDT - 7 months ago

Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025

FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer

Sep 29, 2025, 8:05 AM EDT - 8 months ago

FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer

Guardant Health Transcript: Investor Day 2025

Sep 24, 2025, 9:00 AM EDT - 8 months ago

Guardant Health Transcript: Investor Day 2025

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

Sep 24, 2025, 8:05 AM EDT - 8 months ago

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

DGX

Alex M. Azar II Joins Guardant Health Board of Directors

Sep 15, 2025, 4:07 PM EDT - 8 months ago

Alex M. Azar II Joins Guardant Health Board of Directors

Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership

Sep 11, 2025, 8:05 AM EDT - 8 months ago

Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership

Guardant Health Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 4:05 PM EDT - 8 months ago

Guardant Health Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

Sep 8, 2025, 8:05 AM EDT - 8 months ago

Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test

Sep 4, 2025, 8:06 AM EDT - 8 months ago

Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test

Guardant Health to Host Investor Day on September 24, 2025

Aug 28, 2025, 4:05 PM EDT - 9 months ago

Guardant Health to Host Investor Day on September 24, 2025

Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 26, 2025, 4:05 PM EDT - 9 months ago

Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Guardant Health Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 13, 2025, 9:30 AM EDT - 9 months ago

Guardant Health Transcript: Canaccord Genuity’s 45th Annual Growth Conference

American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity

Aug 4, 2025, 8:06 AM EDT - 10 months ago

American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity

Gator5326
Gator5326 May. 13 at 1:54 PM
$GH As of May 2026, Guardant Health (GH) stock is experiencing strong bullish sentiment with multiple price target increases following Q1 2026 results that showed 48% year-over-year revenue growth. Analysts have raised targets to a range of $130–$180, indicating a potential 29%-47% upside driven by strong oncology test volumes and Shield screening momentum.
0 · Reply
BeeDecay
BeeDecay May. 13 at 11:44 AM
$PSNL $NTRA $GH , With IO reimbursement in place now it might be the case that little Personalis will eat some of the others' lunch quite soon.
0 · Reply
Gator5326
Gator5326 May. 12 at 10:21 PM
$GH https://bofa.veracast.com/webcasts/bofa/healthcare2026/15d168.cfm 🚀🚀🚀
0 · Reply
Gator5326
Gator5326 May. 12 at 10:20 PM
$GH ACS ACS ACS 😎😎😎
0 · Reply
Shlobby
Shlobby May. 12 at 2:40 PM
$GH took some oct calls
0 · Reply
CapitalMonk
CapitalMonk May. 12 at 1:03 AM
$GH Price: $96.71 (+1.06%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.48% RSI: 62.1 | Momentum: Strong Momentum Volume: +1.5% vs avg Volatility: 2.84% Support: $79.01 | Resistance: $98.50 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
WOLFSTREET
WOLFSTREET May. 11 at 6:02 PM
$GH Press Like!
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 12:47 PM
$GH Current Stock Price: $95.78 Contracts to trade: $95.0 GH May 15 2026 Call Entry: $3.15 Exit: $4.46 ROI: 42% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
vjtweet
vjtweet May. 8 at 4:54 PM
$GH not blowout results.. but should continue the upward path. Holding a position. To add above 100.
1 · Reply
JFDI
JFDI May. 8 at 1:50 PM
$GH 30/40wk SMA to stage 2 continuation.
1 · Reply
LadyBABA
LadyBABA May. 7 at 10:49 PM
$GH Natera did a million tests this quarter, crazy
1 · Reply
Gator5326
Gator5326 May. 7 at 9:31 PM
$GH ACS approval any day and yhen
2 · Reply
GoldenBum77
GoldenBum77 May. 7 at 9:10 PM
$GH
0 · Reply
OffHisGame88
OffHisGame88 May. 7 at 8:43 PM
$GH very boolosh
0 · Reply
Gator5326
Gator5326 May. 7 at 8:37 PM
$GH 86000 tests !!! In ONE month! 😎
1 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 7 at 8:20 PM
$GH Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.85 down -10.39% YoY • Reported revenue of $301.67M up 48.26% YoY • Guardant Health raised its full year 2026 revenue guidance to $1.30 to $1.32B, representing 32% to 34% growth, and expects oncology volume to grow greater than 35%.
0 · Reply
Gator5326
Gator5326 May. 7 at 8:12 PM
$GH First quarter 2026 revenue growth of 48% driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to $1.30 to $1.32 billion, representing growth of 32% to 34%
0 · Reply
Gator5326
Gator5326 May. 7 at 7:23 PM
$GH ready for strong numbers? upward yearly revision? 😎
0 · Reply
ToddSl
ToddSl May. 7 at 7:22 PM
$GH Any insights into the 5 year Cup and Handle that looks to be forming?
0 · Reply
WantedToRetireEarly
WantedToRetireEarly May. 7 at 3:39 PM
$GH Guardant Health (GH) is scheduled to announce Q1 earnings results on Thursday, May 7th, after market close. The consensus EPS Estimate is -$0.47 (+4.1% Y/Y) and the consensus Revenue Estimate is $279.06M (+37.2% Y/Y). Over the last 2 years, GH has beaten EPS estimates 75% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 3 upward revisions and 8 downward. Revenue estimates have seen 9 upward revisions and 5 downward.
0 · Reply
Gator5326
Gator5326 May. 4 at 12:28 PM
$GH https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZyHSCsppSPtyeGddfxO4qyf7-2BfqgDTPA1pwQgPEK0LIAPgMiX4-2F-2BPEeswKNgeDQKKpDSOkaVixtbCm896QhVPyu8cAtperEDlojQ-2FSZO-2FneVXoTcmjz0kB0ITeRnsicx1pXMPWdzlYytBnOiH9r0QYqoOz9RBX98hi2-2Bavfx7rWdRoWUGJ-2B1LvL5uD5O7AF9tS0dnjS7L10EO7Il5fVtyAMHD7KnnEiywB9dR6MnbcjPsHVSLP-2BtsjkjxWyJOFB2uk3yRuFeWj3dJgixpqfpKPd2EWkkm2EaQWtHBcTlscJmloz4rKVB9fBEy1qeea5LDg-3D-3DTUSn_n7gaS9t6bMxECCQWPRdwdqPZyOAjF4RSivuNxLLPR-2FSmysoqQW1ClVyewMaUHyr5PXnLg-2BfGbSor9w1GLElWTiEw3tZro1MLP1IzWdS5qPpbfYGAtnJcrhAqCrHeCZaHRgIG36Opi-2BfPD0wkS0BpMmexHyqRpwNsuVxXv-2FLsvrf-2Byk7vtMdmudRs6NqBY1c-2F9j4PNd0jNGIZjhQN8frnbNyzr4S5AI7VRS2u0QkGhPREwUEXtipatwKbAQNAhwIStjueHTF8aDv7JADM9MgqEVT5s8nPxyCTX-2BtOtMmRTPsT2GQe5oF3kwTH4oQo5aDxsUnHpsrO7Ma6og9JM3yb2kiyeDD9QWqZfFbKeYr6FF4gvtZ9J4MTBvUzHCz3GlYSUXikPdIUBJVl3xMh3SRD3RElwrytSB5Uu3vPCum1w8WJqa-2BGOu-2FrzWI-2F9MhC9DgiRzkiGXqIfM5cXOF2AGnW9ggQ-2Bc2qcnRQg-2FTbK3nkGOz-2BsSCOYHeMChIpvheEH2VIhC4E6kNpVI24GYU-2FRzm-2FMUpWcBfFrHm313N6Rr6qiWAwQsL5wd-2BKsrYohLQ3G7jd
0 · Reply
Bom_Jesus
Bom_Jesus May. 1 at 2:36 PM
$GH
0 · Reply